News Story: Full Text
Sponsored By
Cedars-Sinai Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website


Allos Therapeutics, Inc. to Present at the SG Cowen 21st Annual Health Care Conference in Boston (PR Newswire)...The presence of oxygen in tumors is an essential element for the effectiveness of radiation therapy and some chemotherapy in the treatment of cancer.......Unlike chemotherapeutics or other radiosensitizers, RSR13 does not have to cross the blood brain barrier and enter the tumor for efficacy....- Mar 12 8:03 AM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/prnews/010312/lam028_2.html

Posted on: 03/12/2001

"Yahoo - Allos Therapeutics, Inc. to Present at the SG Cowen 21st Annual Health Care Conference in Boston"
Yahoo! Finance Finance Home - Yahoo! - Help
PR Newswire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
ALTH
5 1/8
+1/4
delayed 20 mins - disclaimer
Monday March 12, 8:03 am Eastern Time

Press Release

SOURCE: Allos Therapeutics, Inc.

Allos Therapeutics, Inc. to Present at the SG Cowen 21st Annual Health Care Conference in Boston

DENVER, March 12 /PRNewswire/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH - news) will present at the SG Cowen 21st Annual Health Care Conference at The Marriott Copley Place Hotel in Boston at 10:15 a.m. and 11:15 a.m. Eastern Time on Tuesday, March 13, 2001.

The Allos presentation will be given by Michael E. Hart, Chief Financial Officer and Senior Vice President, Operations.

Allos Therapeutics is a pharmaceutical company focused on developing and commercializing innovative small molecule drugs, initially for improving cancer treatments. Allos' lead drug under development is RSR13. RSR13 is a synthetic small molecule that increases the release of oxygen from hemoglobin, the oxygen carrying protein contained within red blood cells. The presence of oxygen in tumors is an essential element for the effectiveness of radiation therapy and some chemotherapy in the treatment of cancer. By increasing tumor oxygenation, RSR13 has the potential to enhance the efficacy of standard radiation therapy and certain chemotherapeutic drugs. Unlike chemotherapeutics or other radiosensitizers, RSR13 does not have to cross the blood brain barrier and enter the tumor for efficacy. Enhancement of oxygen release from hemoglobin to oxygenate the tumor is the means of enhancing the effectiveness of radiation therapy and chemotherapy.

SOURCE: Allos Therapeutics, Inc.

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:Allos Therapeutics Inc (NasdaqNM:ALTH - news)
Related News Categories: biotech, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740